# BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

> **NCT00526149** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 76 (actual)

## Conditions studied

- Breast Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Melanoma (Skin)
- Ovarian Cancer
- Sarcoma

## Interventions

- **DRUG:** BI 2536
- **OTHER:** high performance liquid chromatography
- **OTHER:** mass spectrometry
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00526149
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2013-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526149, "BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00526149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*